The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).
A. Desjardins
No relevant relationships to disclose
D. A. Reardon
Consultant or Advisory Role - Roche/Genentech; Schering-Plough
Honoraria - Roche/Genentech; Schering-Plough
J. J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
K. Peters
No relevant relationships to disclose
M. Trikha
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
J. James
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
M. Gardner
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
A. Brickhouse
No relevant relationships to disclose
J. E. Herndon
No relevant relationships to disclose
H. S. Friedman
Consultant or Advisory Role - Genentech
Honoraria - Genentech